share_log

Candel Therapeutics Presents Preclinical Data From Its EnLIGHTEN Discovery Platform at SITC; The First Experimental Agent Is Alpha-201-Macro1, An Investigational Viral Immunotherapy Designed To Activate Innate Immune Surveillance

Candel Therapeutics Presents Preclinical Data From Its EnLIGHTEN Discovery Platform at SITC; The First Experimental Agent Is Alpha-201-Macro1, An Investigational Viral Immunotherapy Designed To Activate Innate Immune Surveillance

Candel Therapeutics公佈了來自SITC的Enlighten發現平台的臨床前數據;第一種實驗藥物是Alpha-201-Macro1,這是一種旨在激活先天免疫監測的在研病毒免疫療法
Benzinga ·  2023/11/06 08:31
Candel Therapeutics公佈了來自SITC的Enlighten發現平台的臨床前數據;第一種實驗藥物是Alpha-201-Macro1,這是一種旨在激活先天免疫監測的在研病毒免疫療法
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論